{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:14:03Z","timestamp":1766747643566,"version":"3.48.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"DOI":"10.7759\/cureus.100109","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:09:44Z","timestamp":1766747384000},"source":"Crossref","is-referenced-by-count":0,"title":["A Pathological Complete Response After Pembrolizumab for DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Colorectal Cancer Enabling Curative Surgery: A Case Report"],"prefix":"10.7759","author":[{"given":"Bernard L","family":"Hanekom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Coveney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller LH","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021, 325:669-85. 10.1001\/jama.2021.0106","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100712","article-title":"Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H\/dMMR metastatic colorectal cancer","volume":"36","author":"Amonkar MM","year":"2023","unstructured":"Amonkar MM, Chase M, Myer NM, Wang T, Turzhitsky V, Spira A. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H\/dMMR metastatic colorectal cancer. Cancer Treat Res Commun. 2023, 36:100712. 10.1016\/j.ctarc.2023.100712","journal-title":"Cancer Treat Res Commun"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11888-019-00437-z","article-title":"Immune checkpoint inhibitors in metastatic colorectal cancer: current status, recent advances, and future directions","volume":"10","author":"Kamatham S","year":"2019","unstructured":"Kamatham S, Shahjehan F, Kasi PM. Immune checkpoint inhibitors in metastatic colorectal cancer: current status, recent advances, and future directions. Curr Colorectal Cancer Rep. 2019, 10:112-21. 10.1007\/s11888-019-00437-z","journal-title":"Curr Colorectal Cancer Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193153","article-title":"Immunotherapy-induced complete response in dMMR rectal cancer-a surgical dilemma?","volume":"17","author":"Loufopoulos P","year":"2025","unstructured":"Loufopoulos P, Perivoliotis K, Chatziathanasiou D, et al.. Immunotherapy-induced complete response in dMMR rectal cancer-a surgical dilemma?. Cancers (Basel). 2025, 17:3153. 10.3390\/cancers17193153","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9 T","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al.. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020, 383:2207-18. 10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre T","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, et al.. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024, 391:2014-26. 10.1056\/NEJMoa2402141","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9 T","year":"2023","unstructured":"Andr\u00e9 T, Berton D, Curigliano G, et al.. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open. 2023, 6:e2341165. 10.1001\/jamanetworkopen.2023.41165","journal-title":"JAMA Netw Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13332","article-title":"A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient\/microsatellite instability-high metastatic colon cancer: a case report","volume":"24","author":"Igaue S","year":"2022","unstructured":"Igaue S, Okuno T, Ishibashi H, et al.. A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient\/microsatellite instability-high metastatic colon cancer: a case report. Oncol Lett. 2022, 24:211. 10.3892\/ol.2022.13332","journal-title":"Oncol Lett"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1064488","article-title":"Case report: complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation","volume":"13","author":"Xu Y","year":"2022","unstructured":"Xu Y, Li Q, Zhao J, Ni X, Li P, Hu W. Case report: complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation. Front Immunol. 2022, 13:1064488. 10.3389\/fimmu.2022.1064488","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i30.110330","article-title":"Spontaneous colonic transection following pathologic complete response to pembrolizumab in high microsatellite instability colorectal cancer: a case report and review of literature","volume":"13","author":"Lee C","year":"2025","unstructured":"Lee C, Kim MH, Choi ET, et al.. Spontaneous colonic transection following pathologic complete response to pembrolizumab in high microsatellite instability colorectal cancer: a case report and review of literature. World J Clin Cases. 2025, 13:110330. 10.12998\/wjcc.v13.i30.110330","journal-title":"World J Clin Cases"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449627-a-pathological-complete-response-after-pembrolizumab-for-dna-mismatch-repair-deficientmicrosatellite-instability-high-colorectal-cancer-enabling-curative-surgery-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:09:44Z","timestamp":1766747384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449627-a-pathological-complete-response-after-pembrolizumab-for-dna-mismatch-repair-deficientmicrosatellite-instability-high-colorectal-cancer-enabling-curative-surgery-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.100109","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}